Payment overview · 2025
General Payments
$1,220.72
67 reported records · 13 companies
Healthcare provider profile · identity verified
William Flowers, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JAMESTOWN, TN · NPI 1962855445
Verified facts
What the public records show
CMS Open Payments records show William Flowers, FNP-C received $1,220.72 in general payments during 2025 across 67 reported records.
Novo Nordisk Inc accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Korlym, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Korlym by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $271.49 | 22.2% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $204.07 | 16.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $193.47 | 15.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $175.66 | 14.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.75 | 6.6% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $63.01 | 5.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.47 | 4.9% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.88 | 4.4% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.34 | 3.3% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $24.66 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.75 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.75 | 1.3% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $14.42 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,200.50 | 66 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $253.39 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $204.07 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $182.83 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $153.80 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.87 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.62 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $63.01 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.47 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.47 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.60 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.88 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.10 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 143 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 152 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
143 | 36 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
152 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 277 | 79 |
| Lisinopril | Lisinopril | 272 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 263 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 116 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 219 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 210 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 70 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 189 | 48 |
| Alprazolam | Alprazolam | 187 | 42 |
| Omeprazole | Omeprazole | 185 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 77 |
| Furosemide | Furosemide | 167 | 75 |
| Jardiance | Empagliflozin | 152 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 73 |
| Farxiga | Dapagliflozin Propanediol | 143 | 36 |
| Mounjaro | Tirzepatide | 135 | 39 |
| Ozempic | Semaglutide | 132 | 37 |
| Eliquis | Apixaban | 125 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 51 |
| Losartan Potassium | Losartan Potassium | 116 | 57 |
| Montelukast Sodium | Montelukast Sodium | 108 | 42 |
| Famotidine | Famotidine | 101 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 38 |
| Potassium Chloride | Potassium Chloride | 98 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 39 |
| Metformin Hcl | Metformin Hcl | 87 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 28 |
| Pregabalin | Pregabalin | 82 | 26 |
| Trazodone Hcl | Trazodone Hcl | 81 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 30 |
| Sertraline Hcl | Sertraline Hcl | 78 | 35 |
| Carvedilol | Carvedilol | 73 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 32 |
| Clonazepam | Clonazepam | 70 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 38 |
| Diazepam | Diazepam | 68 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 16 |
| Meloxicam | Meloxicam | 67 | 36 |
| Simvastatin | Simvastatin | 67 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 21 |
| Cefdinir | Cefdinir | 63 | 57 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 17 |
| Nystatin | Nystatin | 61 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 51 |
| Trulicity | Dulaglutide | 60 | 18 |
| Allopurinol | Allopurinol | 59 | 26 |
| Buspirone Hcl | Buspirone Hcl | 59 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 26 |
| Methylprednisolone | Methylprednisolone | 57 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 31 |
| Amoxicillin | Amoxicillin | 52 | 46 |
| Fluconazole | Fluconazole | 52 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 42 |
| Prednisone | Prednisone | 49 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 26 |
| Novolog Flexpen | Insulin Aspart | 48 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 16 |
| Linzess | Linaclotide | 47 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 23 |
| Lorazepam | Lorazepam | 46 | 12 |
| Atenolol | Atenolol | 44 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 23 |
| Mirtazapine | Mirtazapine | 42 | 16 |
| Glipizide | Glipizide | 39 | 14 |
| Ibuprofen | Ibuprofen | 39 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 17 |
| Lovastatin | Lovastatin | 37 | 14 |
| Metformin Hcl Er | Metformin Hcl | 37 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 15 |
| Rybelsus | Semaglutide | 36 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Glimepiride | Glimepiride | 33 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Sucralfate | Sucralfate | 30 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 14 |
| Glipizide Er | Glipizide | 28 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 14 |
| Xarelto | Rivaroxaban | 28 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | 13 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Ezetimibe | Ezetimibe | 22 | 13 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | 12 |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 12 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Estradiol | Estradiol | 20 | 11 |
| Kerendia | Finerenone | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | 11 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Korlym | Mifepristone | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,220.72 · 67 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, DUPIXENT, FARXIGA, GIMOTI, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error